Cambridge Healthtech Institute’s Inaugural

Oncolytic Viral Therapy
( 溶瘤病毒疗法 )

Engineering, Translational and Clinical Strategies

2019年4月10～11日

Oncolytic virotherapy may be the next major breakthrough in immunotherapy. Long viewed as tools for directly killing cancer cells, recent research indicates that oncolytic viruses may have a bigger role to play by triggering an immune response in the body against cancer. Interest in the field is at an all-time high, evidenced by the entry of big pharma the likes of Amgen, Pfizer, Celgene, BMS, as well as many smaller but highly active biotech companies.

Acknowledging the importance and growing interest in this field, CHI is bringing the first annual Oncolytic Viral Therapy to PEGS Boston. The conference will present exciting research and development in the field, from mechanistic understanding of viruses and tumor biology to engineering and optimization strategies, preclinical and translational sciences, clinical trial updates and challenges.

Preliminary Agenda

KEYNOTE PRESENTATION: Next-Generation OV and New Combinational Approaches for Treatment of Solid Tumors

Paola Grandi, PhD, CSO, Cold Genesys

NOVEL APPROACHES FOR ONCOLYTIC VIRUSES

Antibody Targeted Viruses: The Next Generation of Oncolytics

Stephen Russell, MD, PhD, CEO, Vyriad

Talimogene Laherparepvec - The Journey So Far and The Horizon Beyond

Sumita Bhatta, PhD, Clinical Research Medical Director, Amgen Inc.

T-SIGn Virus Approach to Cancer Gene Therapy – Driving the Tumor Cells to Express Combinations of Biological Therapeutics within the Tumor Microenvironment

Brian Champion, PhD, CSO, PsiOxus

Oncolytic Virus Vaccines

John C. Bell, PhD, Prof, Medicine & Biochemistry, Microbiology & Immunology, Ottawa Hospital Research Institute, University of Ottawa

TARGETING THE TUMOR MICROENVIRONMENT

Inflaming the Tumor Microenvironment to Augment Oncolytic Virotherapy

Timothy Cripe, MD, PhD, Chief, Hematology and Oncology, Nationwide Children’s Hospital

VSV-GP Eradicates the Tumor and Stimulates an Immune Response

Patrik Erlmann, PhD, Head, R&D, ViraTherapeutics GmbH

COMBINATION VIROTHERAPY WITH IMMUNOTHERAPY

Exploring Virotherapy/Immunotherapy Combinations for The Treatment of Glioblastoma

Sean Lawler, PhD, Asst Prof, Managing Director, Harvey Cushing Neurooncology Laboratories, Department of Neurosurgery, Brigham and Women’s Hospital

Combination of Adenovirus Oncolytic Virotherapy with CDK4/6 Inhibitors: An Unexpected and Incredible Strong Treatment Alliance

Per Sonne Holm, PhD, Head, Virotherapy Research Group, Urology, Technical University Munich

Oncolytic Poliovirus Combined with PD1/PDL1 Blockade for Cancer Therapy

Smita Nair, PhD, Prof, Surgery, Neurosurgery and Pathology, Duke University School of Medicine

PRECLINICAL AND CLINICAL PROGRESS

Development of Patient-Derived Glioblastoma Model Systems to Predict Response to OV Therapy

Martine Lamfers, PhD, Prof, Neurosurgery, Erasmus MC

Lessons Learned from a Phase I Trial of Intratumoral and Intravenous Oncolytic Herpes Virus in Children and Young Adults

Keri Streby, MD, Pediatric Hematologist-Oncologist, Nationwide Chiildren’s Hospital

* 活动内容有可能不事先告知作更动及调整。